Parameter | Geometric Mean (CV%) 230 mg LY2603618 |
|---|
Cycle 1 |
|---|
Day 2 | Day 16 |
|---|
(n = 58) | (n = 48) |
|---|
Cmax (ng/mL) | 3170 (50) | 3410 (50) |
tmax
a (h) | 1.00 (0.88–1.38) | 1.00 (0.88–1.83) |
Cav,24 (ng/mL) | 966 (68) d
| 987 (60) e
|
AUC(0–24) (ng*h/mL) | 23200 (68) d
| 23700 (60) e
|
AUC(0-∞) (ng*h/mL) | 29400 (84) d
| 29100 (74) e
|
AUC(tlast-∞) (%) | 14.3 (131) d
| 12.0 (152) e
|
CL (L/h) | 7.79 (84) d
| 7.87 (74) e
|
Vss (L) | 104 (48) d
| 95.1 (42) e
|
t1/2 (h) | 9.67 (48) d
| 8.86 (48) e
|
RA
b
| – | 108 (32) f
|
RA
c
| – | – |
-
AUC
(0 - ∞)
area under the plasma concentration time-curve from time 0 to infinity; AUC
(0–24)
area under the plasma concentration time-curve from time 0 to 24 h; AUC
(tlast - ∞)
fraction of AUC(0 - ∞) extrapolated from the time of the last measurable plasma concentration (tlast) to infinity; C
av,24
average plasma concentration over 24 h calculated using AUC(0–24); CL systemic clearance; C
max
maximum plasma concentration; CV% percent coefficient of variation; m
2 meters squared; mg milligrams; n number of pharmacokinetic observations; NC not calculated; R
A
accumulation ratio; t
max
time of maximum observed plasma concentration; V
ss
volume of distribution at steady state following intravenous (IV) administration; t
1/2
elimination half-life
-
aMedian (range)
-
bIntracycle accumulation ratio [Cycle 1 Day 16 AUC(0 - ∞)/Cycle 1 Day 2 AUC(0 - ∞)]
-
cIntercycle accumulation ratio [Cycle 2 Day 2 AUC(0 - ∞)/Cycle 1 Day 2 AUC(0 - ∞)]
-
d
n = 54
-
e
n = 42
-
f
n = 38
